CytomX Therapeutics
CTMXClinical Pipeline
Program / Asset
Target Indications
Development Phase
Financial Statements & Analysis
Total Gross Revenue
$18.66M $5.96M $76.20M $10.26M
Cost of Revenue / Sales
— — — —
Gross Profit
— — — —
OPERATING EXPENSES
2025-06-302025-09-302025-12-312026-03-31
Research & Development (R&D)
($13.32M) ($15.30M) ($68.73M) ($19.24M)
Selling & Marketing Expense
— — — —
General & Administrative (G&A)
($6.62M) ($6.43M) ($29.84M) ($10.69M)
Operating Income / (Loss)
($1.29M) ($15.77M) ($22.36M) ($19.67M)
NON-OPERATING & FINANCING ITEMS
2025-06-302025-09-302025-12-312026-03-31
Interest Income / Cash Yields
$1.18M $1.59M $5.21M $1.49M
Interest & Debt Servicing Expense
— — — —
Other Non-Operating Income / (Expense)
$0.02M $0.01M $0.03M ($0.01M)
Income Tax Provision / (Benefit)
$0.06M $0.06M $0.24M $0.06M
NET INCOME / (NET LOSS)
($0.15M) ($14.23M) ($17.37M) ($18.25M)
ASSETS (CURRENT & FIXED)
2025-06-302025-09-302025-12-312026-03-31
Cash and Cash Equivalents
$49.0M$34.2M$12.7M$28.8M
Short-Term Marketable Investments
// --// --// --// --
Total Liquid Cash Resources
$49.0M$34.2M$12.7M$28.8M
Accounts Receivable, Net
$1.9M$1.6M$2.0M$0.6M
Prepaid Expenses & Other Current Assets
$4.7M$4.0M$4.9M$5.7M
Total Current Assets
$164.6M$149.2M$143.9M$353.1M
Property, Plant and Equipment, Net
$1.9M$1.7M$1.3M$1.1M
Intangibles & Other Non-Current Assets
// --// --// --// --
TOTAL CONSOLIDATED ASSETS
$175.1M$158.3M$151.6M$359.4M
LIABILITIES & STOCKHOLDERS' EQUITY
2025-06-302025-09-302025-12-312026-03-31
Accounts Payable
$0.2M$0.6M$1.3M$1.4M
Accrued Expenses & Clinical Liabilities
$11.5M$12.4M$14.2M$11.9M
Total Current Liabilities
$39.2M$41.0M$46.6M$34.0M
Long-Term Corporate Debt Balances
// --// --// --// --
Deferred Revenue & Collaboration Liabilities
// --// --// --// --
Other Long-Term Obligations
$15.9M$9.8M$5.9M$5.4M
Total Liabilities Block
$55.1M$50.9M$52.6M$39.4M
Total Stockholders' Equity
$119.9M$107.4M$99.0M$319.9M
TOTAL LIABILITIES & EQUITY
$175.1M$158.3M$151.6M$359.4M
HISTORICAL RATIO ANALYSIS
2025-06-302025-09-302025-12-312026-03-31
Current Liquidity Ratio
4.20x 3.64x 3.09x 10.38x
R&D Expenditure Flow
$32.2M$47.5M$68.7M$19.2M
Net Income / (Loss)
($0.15M) ($14.23M) ($17.37M) ($18.25M)
Depreciation & Amortization
— — $1.20M —
Stock-Based Compensation
$3.44M $4.82M $6.30M $4.71M
Change in Accounts Receivable
($1.23M) ($1.47M) ($1.09M) ($1.37M)
Change in Prepaid Assets / Expenses
$1.08M $0.37M $1.24M $0.89M
Change in Payables & Clinical Accruals
($0.85M) ($0.43M) $0.22M $0.07M
Other Operating Source / (Use) Changes
($39.07M) ($41.40M) ($66.09M) ($11.59M)
Net Cash from Operating Activities
($36.80M) ($52.34M) ($75.59M) ($25.55M)
INVESTING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Capital Expenditures (CapEx)
($0.15M) ($0.02M) ($0.22M) $0.00M
Purchases of Marketable Securities
— — — —
Maturities & Sales of Investments
— — — —
Net Cash from Investing Activities
($45.76M) ($45.33M) ($59.74M) ($192.78M)
FINANCING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Proceeds from Issuing Debt Instruments
— — — —
Repayments of Debt / Leases
— — — —
Proceeds from Issuing Stock / ATM Options
$93.37M $93.37M $109.64M $228.35M
Net Cash from Financing Activities
$93.55M $93.80M $110.45M $234.49M
NET CONSOLIDATED CHANGE IN CASH
— — — —
Clinical Trials Registry
Registry ID
Phase / Asset
Status